Efficacy of two barrier iodine teat dips under natural exposure conditions.

The efficacy of 2 iodine barrier teat dips was compared with a conventional iodine postmilking teat dip. The products were evaluated using a natural exposure trial on a 250-cow dairy based on the National Mastitis Council guidelines. Bacteriological samples were taken every 2 wk over 6 mo. All dips contained 1.0% available iodine and high levels of free iodine for germicidal efficacy. Barrier 1 was an experimental dip containing 14 to 20 ppm of free iodine, barrier 2 contained 8 to 14 ppm of free iodine, and the nonbarrier control contained 12 to 16 ppm of free iodine. The average free iodine for barrier 1 and barrier 2 combined was 14 ppm, which was equal to the average free iodine for the positive control. A 21% reduction of new intramammary infections (IMI) was observed for the 2 barrier dips combined when compared with the nonbarrier control. A significant reduction of 38% was observed for the clinical infection rate for barrier 1 when compared with barrier 2; however, barrier 1 did not significantly reduce the subclinical IMI when compared with barrier 2. Barrier 1 significantly reduced the combined clinical and subclinical IMI by 24% when compared with the positive control. The skin condition showed slight variation among the dips over the course of the trial, but no difference was observed at the end of the trial. Barrier 1, with the highest concentration of free iodine, gave the best efficacy results of all 3 dips.

Efficacy of two iodine teat dips based on reduction of naturally occurring new intramammary infections.

The efficacy of 2 teat dips, product 1 (Della Care with 5 to 8 ppm of free iodine, used as a positive control) and product 2 (New Della Care with 12 to 16 ppm of free iodine), was compared using a natural exposure trial on dairy cattle. The trial was based on National Mastitis Council guidelines and performed over 9 mo. Both teat dips contained 0.25% iodine. Product 2 reduced the infection rate 57.6% for major pathogens and 53.7% for minor pathogens, compared with the positive control. Product 2 gave highly significant reductions for Staphylococcus aureus, coagulase-negative staphylococci, and Corynebacterium bovis. Teat skin, teat ends, and teat hyperkeratosis were evaluated during trial. No significant difference in teat condition was observed between these 2 products.

Efficacy of a 0.1% iodine teat dip against Staphylococcus aureus and Streptococcus agalactiae during experimental challenge.

An experimental challenge trial was performed according to the guidelines recommended by the National Mastitis Council (NMC). A 0.1% iodine teat dip (Quartermate with I-Tech) was examined. This product gave an 87.9% reduction of new intramammary infections with Staphylococcus aureus and a 66.5% reduction for Streptococcus agalactiae compared with a negative control. Teat end and teat skin characteristics remained excellent throughout the trial.

Efficacy of two iodine teat dips during experimental challenge with Staphylococcus aureus and Streptococcus agalactiae.

An experimental challenge trial was performed against Staphylococcus aureus and Streptococcus agalactiae following the procedures recommended by the National Mastitis Council. The efficacy of two teat dips, product 1 (Bovadine with I-Tech II) and product 2 (Bovadine with I-Tech, used as a positive control), was determined. Both teat dips contain 1% iodine and 10% glycerin. Product 1 established an 89.7% reduction in infections against Staph. aureus and 73.1% reduction in infections against Strep. agalactiae. Product 2 demonstrated an 86.2% reduction in infections against Staph. aureus and 78.4% reduction in infections against Strep. agalactiae. Teat skin and teat ends were evaluated before and after the trial. No significant change in teat condition was observed for either product.

Immunodiagnostic evaluation in women with reproductive failure.

PROBLEM: Several immunological factors have been associated with diagnostic subpopulations of reproductive failure. It is important to determine a trend of immunological abnormalities among these subpopulations. The purpose of this study is to assist in the selection of treatment for patients suspected of having specific diagnoses of reproductive failure. METHOD OF STUDY: Blood samples from 591 patients were evaluated for the presence of antiphospholipid (APA), antinuclear (ANA), and antithyroid (ATA) antibodies, as well as for lupus anticoagulant (LA), embryotoxic factors (ETF), and elevated levels of natural killer (NK) (CD56+) cells, and all tests were performed as a panel. The patients were grouped into the following diagnostic categories: recurrent pregnancy loss (n = 302), IVF/ET failure (IVFf, n = 122), unexplained infertility (n = 97), ovarian dysfunction (n = 47), and endometriosis (n = 23). The thresholds for positivity and the prevalence of the tested factors among normal healthy populations have been established by testing 100 or more healthy male and female individuals with each one of the tests used (general population control). All tests as panel were performed on 20 normal fertile female individuals as controls (fertile female controls). RESULTS: Of all patients with reproductive failure, 75.6% had at least one abnormal test. The most frequent abnormal result was found to be the elevation of NK (CD56+) cells (37%), followed by ANA (34%), APA (24%), ATA (19%), and ETF (11%). Of the recurrent pregnancy loss patients, 74.2% had at least one positive abnormal result from all of the tests performed: overall, 70% of women with IVF failure had at least one abnormal test; of patients diagnosed with unexplained infertility, approximately 81% had at least one abnormal result; 74.4% of the patients with ovarian dysfunction and 52% of the patients with endometriosis had at least one abnormal result. From normal fertile controls, 10% showed at least one abnormal test result. CONCLUSION: APA, ANA, ATA, ETF, and elevated NK (CD56 ) cells are significantly more prevalent among women experiencing reproductive failure than among the control group and normal healthy individuals.

Antiphospholipid antibodies associated with implantation failure after IVF/ET.

PURPOSE: Our purpose was to determine the specific antiphospholipid antibodies (APAs) that should be evaluated to identify individuals at risk for implantation failure associated with reproductive autoimmune failure syndrome (RAFS). METHODS: The prevalence of APAs among 312 women with implantation failure was compared with that of 100 fertile control women. To be included in the implantation failure group, each woman had to have had at least 12 embryos transferred without subsequent positive pregnancy test. Enzyme-linked immunoabsorbant assay was used to measure IgG, IgM, and IgA anticardiolipin, antiphosphatidyl ethanolamine, antiphosphatidyl inositol, antiphospatidic acid, anti-phosphatidyl glycerol, antiphosphatidyl choline, and antiphosphatidyl serine. RESULTS: When the values for each of the seven APAs in three isotypes were compared between women with implantation failure and the control population, all of the APAs tested had a significantly higher frequency among women with implantation failure. Positive APAs were detected in 69 (22%) of the 312 women with implantation failure compared with 5 (5%) of the 100 control women (P < 0.0001). Anticardiolipin antibodies were found in 13 (4%) of the 312 women with implantation failure and none of the controls. Fifty-six (18%) of the 312 with implantation failure were negative for anticardiolipin antibodies but had positive values of other APAs. CONCLUSIONS: A complete APA panel using seven isotypes is necessary for diagnosing implantation failure associated with RAFS. If only anticardiolipin antibody is measured, 4% (13/312) of the positive APAs are detected, and 81% (56/69) of women with implantation failure associated with RAFS will have the diagnosis missed.